Loading...
Loading...
RAPT| Name | Value |
|---|---|
| Revenues | 5.3M |
| Cost of Revenue | 0.3M |
| Gross Profit | 5.0M |
| Operating Expense | 32.9M |
| Operating I/L | -33.2M |
| Other Income/Expense | 2.3M |
| Interest Income | 0.0M |
| Pretax | -30.9M |
| Income Tax Expense | 2.9M |
| Net Income/Loss | -30.9M |
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Their lead inflammation drug candidate, RPT193, targets CCR4 to inhibit the migration of type 2 T helper cells into inflamed tissues. Additionally, their lead oncology drug candidate, FLX475, is being investigated in Phase 1/2 clinical trials as a monotherapy and in combination with pembrolizumab for advanced cancer patients. The company also focuses on developing a hematopoietic progenitor kinase 1 inhibitor, positioning itself to generate revenue through the sale and licensing of these innovative therapies.
